

U.S. Serial No. 10/627,014  
Attorney Docket No. 102392-200  
2 of 3

**REMARKS**

The Examiner has required a restriction between the following groups of claims:

Group I, claims 1-14, drawn to a method for treating the metabolic syndrome or Type 2 diabetes in a patient, comprising the step of administering a composition comprising: (1) at least one central dopaminergic neuronal activity activator; (2) at least one central noradrenergic neuronal activity inhibitor; and (3) a pharmaceutically acceptable carrier, classified in class 514, subclasses 534, 649, and

Group II, claims 15-20, drawn to a pharmaceutical composition effective for treating the metabolic syndrome or Type 2 diabetes, said composition comprising: (1) at least one central dopaminergic neuronal activity activator; (2) at least one central noradrenergic neuronal activity inhibitor; and (3) a pharmaceutically acceptable carrier, classified in class 514, subclass 534, 649.

Applicant elects without traverse the claims of Group I, claims 1-14 and reserves the right to file continuation applications on unelected claims 15-20 under 35 USC §§120 and 121.

Any fees due with this Reply may be charged to Deposit Account **23-1665** under Customer Number **27267**.


U.S. Serial No. 10/627,014  
Attorney Docket No. 102392-200  
3 of 3

If a telephone conference would aid in the continued prosecution of this application, the Examiner is invited and encouraged to contact Applicant's representative at the telephone number listed below.

Respectfully submitted,

Anthony H. Cincotta

Date: 23 OCT 2006

  
Todd E. Garabedian, Ph.D.  
Reg. No. 39,197  
WIGGIN and DANA LLP  
One Century Tower  
New Haven, CT 06508-1832  
Telephone: (203) 498-4400  
Facsimile: (203) 782-2889

\15546\5\619621.1